Lv1
70 积分 2024-03-05 加入
Epcoritamab: First Approval
1天前
已完结
Characterizing “Adversity” of Pathology Findings in Nonclinical Toxicity Studies
16天前
已完结
FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data
1个月前
已完结
RNA Interference With Zilebesiran for Mild to Moderate Hypertension
2个月前
已完结
Key considerations in the preclinical development of biosimilars
3个月前
已完结
Considerations for Assessment of Reproductive and Developmental Toxicity of Oligonucleotide-Based Therapeutics
3个月前
已完结
Validation for soluble C5b-9 detection and comparative analysis of three quantification methods
4个月前
已完结
Targeting C3a/C5a receptors inhibits human mesangial cell proliferation and alleviates immunoglobulin A nephropathy in mice
4个月前
已完结
Considerations for Assessment of Reproductive and Developmental Toxicity of Oligonucleotide-Based Therapeutics
4个月前
已完结
Recommendations for Safety Pharmacology Evaluations of Oligonucleotide-Based Therapeutics
4个月前
已完结
皖公网安备34019202002308
